What is the official ID of this bill?

The official print number for this legislation is S 2809.

When did the legislative process begin?

The process officially started on 2023-09-14.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/s2809/BILLS-118s2809is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Who is the primary sponsor?

The primary sponsor is Sen. Cornyn, John [R-TX].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 2809

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Expanding Access to All FDA-Approved Opioid Overdose Reversal Medications.

Q: What are the main provisions?

Key points include: Federal grants for fighting the opioid crisis (like State Opioid Response Grants) can now fund the purchase of any FDA-approved drug or device for emergency overdose treatment. The Department of Health and Human Services (HHS) must update existing grant rules by the end of 2023 to remove the limitation to Naloxone. This provides greater flexibility for states and tribes to choose the most effective and accessible life-saving tools.

This law broadens the definition of life-saving opioid overdose reversal agents eligible for federal grant funding. State and Tribal programs fighting the opioid crisis will no longer be restricted to purchasing only Naloxone, but can use funds for any FDA-approved drug or device designed to reverse an overdose. This change aims to increase the availability and variety of life-saving tools in communities struggling with addiction.

Key points

Federal grants for fighting the opioid crisis (like State Opioid Response Grants) can now fund the purchase of any FDA-approved drug or device for emergency overdose treatment.

The Department of Health and Human Services (HHS) must update existing grant rules by the end of 2023 to remove the limitation to Naloxone.

This provides greater flexibility for states and tribes to choose the most effective and accessible life-saving tools.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

HEAL Act of 2023

Print number: S 2809

Sponsor: Sen. Cornyn, John [R-TX]

Process start date: 2023-09-14

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-09-2025

Source data: api.congress.gov

AI work logs for this document launch

Expanding Access to All FDA-Approved Opioid Overdose Reversal Medications.

Key Questions about Expanding Access to All FDA-Approved Opioid Overdose Reversal Medications.